Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Immune System Diseases

Digestive System Diseases

Rare Diseases

Recurrence

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Hypersensitivity

Fallopian Tube Neoplasms

Peritoneal Neoplasms

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Fallopian Tube Diseases

Abdominal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Peritoneal Diseases

Ovarian Cancer

Ovarian Epithelial Cancer

Fallopian Tube Cancer

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Bevacizumab

Antibodies

Folic Acid

Immunoglobulins

Mirvetuximab soravtansine

Vitamin B Complex

Maytansine

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Immunoconjugates

Immunologic Factors

Tubulin Modulators

Antimitotic Agents

Folinic Acid

Folate

Vitamin B9

Mirvetuximab Soravtansine (MIRV) plus Bevacizumab

Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks

Mirvetuximab soravtansine plus Bevacizumab

Participants will receive Bevacizumab 15mg/kg every 3 weeks

ImmunoGen, Inc.

Stefanie White

Jennifer Scalici, MD

Kelly Fillbrandt

Lyndsay Willmott

Peggy Newsom

Babak Edraki, MD

Joshua Cohen, MD

Devansu Tewari

Alexandrea Cronin, MPH, CCRC

Ramez Eskander

Krishnansu Tewari, MD

Mary Herrera

Jonathan Berek, MD

Bianca Alcantar

Carolyn Haunschild

Linda Borus

Scott Jordan, MD

Julia Malfeld

Edward Grendys, MD

Rebecca Deya

Lauren Hand, MD

Yvonne Enriquez Nunez

Brian Slomovitz, MD

Angele Price

Beverly Long, MD

Meaghan Tenney, MD

Lois Winkelman, RN

Summer Dewdney

Katrina Cabrera

John Moroney, MD

Liz Crist

Lisa Landrum, MD

Cynthia Cruz, CCRP

Michael Callahan, MD

Jessica Landgrebe

David Bender, MD

Andrea D Jewell, MD

Karli Herald

Hope Cottrill, MD

Ashley Walton-Robbins

Rachel Miller, MD

Maria Stambaugh

Amelia Jernigan, MD

Rachael Chrzan

Katrina Wade, MD

Leslie Bradford, MD

Laura M Cucci

Fong Liu, MD

Judy Bosley, RN

Pallavi Kumar, MD

Johns Hopkins

Stephanie Gaillard, MD

Tashanna Myers, MD

Esther Peariso

Gregory Gressel, MD

Jinan Ali

Jessica Thomes-Pepin, MD

Kathryn Bartz

Brent Tierney, MD

Shannon Pierpoint

Peter Lim, MD

Christina Seymour

Ilana Cass

Donna McNamara

Simran Kaur

Eleonora Teplinsky, MD

Patty Kiledjian

Sharyn Lewin, MD

Josephine Faruol

Heidi E Godoy, MD

Bhavana Pothuri, MD

Neha Kumarley

Monica Prasad-Hayes, MD

Mary Agnes Templeton

Charline Watts

Veena John, MD

NICOLINA SURIANO

Joyce Barlin, MD

Jada Jones

Linda Van Le, MD

Jennifer Mewshaw

Angeles Alvarez Secord, MD

UCCC CTO

Amanda Jackson, MD

Sam Allinger

Floor Backes, MD

Daniel Geyer

Thomas Reid, MD

Christine Pappaterra

Christina Washington, MD

Melissa Powell

Michael Gold, MD

Jeanne Schaffer

Charles K Anderson, MD

Jennifer Thompson, CRC,RN

Erin A Salinas, MD

Yukie Bean, CCRP

Elizabeth Munro

Madeline Rigatti

Sarah Crafton, MD

Ashley Douglas

Tommy Buchanan

Maria Bell

Robin Patterson

Michael Ulm, MD

Marian Heaven

Lynne Knowles, MD

Deborah Arant-Daigle

Mark J Messing, MD

Nancy Jones

Mark Messing

Lynora (Nori) Sullivan

Noelle G Cloven, MD

Debora E Lind

Antonio Santillan-Gomez, MD

Hannah Snow

Linda Duska, MD

Jenny Marks

Michael McCollum, MD

CTO operations

Leslie Randall, MD

Edith-Romy Nsangou

Prafull Ghatage, MD

Shalyn Dafoe

Jennifer Rauw, MD

Jeff Gardner

Alannah Smrke, MD

Nidhi Kumar-Tyagi, MD

Julie Holiday

Andrew Robinson, MD

Johanne Weberpals, MD

Amit Oza, MD

Lara deGuerke, MD

Diane Provencher, MD

Mohamed Bakir

Lucy Gilbert, MD

Paul Bessette, MD

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called folate receptor alpha (FRα). It is being developed as maintenance therapy for the treatment of subjects with recurrent platinum-sensitive, highgrade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. Patients must have confirmation of FRα positivity by the Ventana FOLR1 Assay.

.

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)

Progression-free survival defined as the time from date of randomization until investigator-assessed progressive disease (PD) or death, whichever occurs first.

Spots Global Cancer Trial Database for mirvetuximab soravtansine plus bevacizumab